Company registration number 06294637 (England and Wales)
ELIXIR TREATMENTS LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024
PAGES FOR FILING WITH REGISTRAR
ELIXIR TREATMENTS LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
ELIXIR TREATMENTS LTD
BALANCE SHEET
AS AT
31 AUGUST 2024
31 August 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
2,437
3,047
Tangible assets
4
22,311
24,346
24,748
27,393
Current assets
Stocks
18,903
24,250
Debtors
5
-
0
1,055
Cash at bank and in hand
83,723
114,135
102,626
139,440
Creditors: amounts falling due within one year
6
(94,222)
(109,140)
Net current assets
8,404
30,300
Total assets less current liabilities
33,152
57,693
Creditors: amounts falling due after more than one year
7
(1,500)
(3,500)
Provisions for liabilities
(6,187)
(7,438)
Net assets
25,465
46,755
Capital and reserves
Called up share capital
8
1
1
Profit and loss reserves
25,464
46,754
Total equity
25,465
46,755

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ELIXIR TREATMENTS LTD
BALANCE SHEET (CONTINUED)
AS AT
31 AUGUST 2024
31 August 2024
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 29 August 2025
Mrs K Harding
Director
Company Registration No. 06294637
ELIXIR TREATMENTS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024
- 3 -
1
Accounting policies
Company information

Elixir Treatments Ltd is a private company limited by shares incorporated in England and Wales. The registered office is c/o Azets, First Floor, International House, 20 Hatherton Street, Walsall, United Kingdom, WS4 2LA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business.

1.3
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
Amortised over 5 years
1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
33% straight line
Plant and equipment
33% straight line
Computers
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

ELIXIR TREATMENTS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

ELIXIR TREATMENTS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
1
Accounting policies
(Continued)
- 5 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
-
0
-
0
3
Intangible fixed assets
Other
£
Cost
At 1 September 2023 and 31 August 2024
8,255
Amortisation and impairment
At 1 September 2023
5,208
Amortisation charged for the year
610
At 31 August 2024
5,818
Carrying amount
At 31 August 2024
2,437
At 31 August 2023
3,047
ELIXIR TREATMENTS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
- 6 -
4
Tangible fixed assets
Leasehold improvements
Plant and equipment
Computers
Total
£
£
£
£
Cost
At 1 September 2023
15,685
70,554
9,058
95,297
Additions
-
0
1,274
-
0
1,274
Disposals
-
0
(225)
-
0
(225)
At 31 August 2024
15,685
71,603
9,058
96,346
Depreciation and impairment
At 1 September 2023
15,685
46,863
8,403
70,951
Depreciation charged in the year
-
0
2,877
432
3,309
Eliminated in respect of disposals
-
0
(225)
-
0
(225)
At 31 August 2024
15,685
49,515
8,835
74,035
Carrying amount
At 31 August 2024
-
0
22,088
223
22,311
At 31 August 2023
-
0
23,691
655
24,346
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
-
0
1,055
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
2,000
2,000
Taxation and social security
12,963
15,584
Other creditors
79,259
91,556
94,222
109,140
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
1,500
3,500
ELIXIR TREATMENTS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
- 7 -
8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
1
1
1
1
9
Related party transactions
Transactions with related parties

The following amounts were outstanding at the reporting end date:

2024
2023
Amounts due to related parties
£
£
Key management personnel
13,724
53,964
2024-08-312023-09-01falsefalsefalse29 August 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityMrs K HardingMr P Harding062946372023-09-012024-08-31062946372024-08-31062946372023-08-3106294637core:IntangibleAssetsOtherThanGoodwill2024-08-3106294637core:IntangibleAssetsOtherThanGoodwill2023-08-3106294637core:LeaseholdImprovements2024-08-3106294637core:PlantMachinery2024-08-3106294637core:ComputerEquipment2024-08-3106294637core:LeaseholdImprovements2023-08-3106294637core:PlantMachinery2023-08-3106294637core:ComputerEquipment2023-08-3106294637core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3106294637core:CurrentFinancialInstrumentscore:WithinOneYear2023-08-3106294637core:Non-currentFinancialInstrumentscore:AfterOneYear2024-08-3106294637core:Non-currentFinancialInstrumentscore:AfterOneYear2023-08-3106294637core:CurrentFinancialInstruments2024-08-3106294637core:CurrentFinancialInstruments2023-08-3106294637core:ShareCapital2024-08-3106294637core:ShareCapital2023-08-3106294637core:RetainedEarningsAccumulatedLosses2024-08-3106294637core:RetainedEarningsAccumulatedLosses2023-08-3106294637core:ShareCapitalOrdinaryShareClass12024-08-3106294637core:ShareCapitalOrdinaryShareClass12023-08-3106294637bus:Director12023-09-012024-08-3106294637core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3106294637core:ComputerSoftware2023-09-012024-08-3106294637core:LeaseholdImprovements2023-09-012024-08-3106294637core:PlantMachinery2023-09-012024-08-3106294637core:ComputerEquipment2023-09-012024-08-31062946372022-09-012023-08-3106294637core:IntangibleAssetsOtherThanGoodwill2023-08-3106294637core:LeaseholdImprovements2023-08-3106294637core:PlantMachinery2023-08-3106294637core:ComputerEquipment2023-08-31062946372023-08-3106294637core:Non-currentFinancialInstruments2024-08-3106294637core:Non-currentFinancialInstruments2023-08-3106294637bus:OrdinaryShareClass12023-09-012024-08-3106294637bus:OrdinaryShareClass12024-08-3106294637bus:OrdinaryShareClass12023-08-3106294637bus:PrivateLimitedCompanyLtd2023-09-012024-08-3106294637bus:SmallCompaniesRegimeForAccounts2023-09-012024-08-3106294637bus:FRS1022023-09-012024-08-3106294637bus:AuditExemptWithAccountantsReport2023-09-012024-08-3106294637bus:CompanySecretary12023-09-012024-08-3106294637bus:FullAccounts2023-09-012024-08-31xbrli:purexbrli:sharesiso4217:GBP